4D Molecular Therapeutics, Inc. 4

Chief Legal Officer Scott Bizily exercised options and sold a total of 3,270 shares of 4D Molecular Therapeutics (FDMT) common stock in same-day, net-zero transactions at around $12 per share under a 10b5-1 plan.

On August 13 and August 17, 2026, Chief Legal Officer Scott Bizily of 4D Molecular Therapeutics, Inc. exercised stock options for 1,635 shares of common stock at $4.14 per share on each date and immediately sold the same 1,635 shares in the open market (a net-zero share change per date), at average prices of $12.00 and $12.20, respectively. These paired transactions appear to be routine option exercises and sales under a 10b5-1 trading plan adopted on January 13, 2026, likely to cover costs or monetize vested options rather than reflect a directional change in ownership. Following these trades and option exercises, Bizily continued to hold 8,617 shares of common stock directly, with the underlying options (at a $4.14 strike price) continuing to vest monthly through March 6, 2029.

Filing Facts

CIK

1650648

Ticker

FDMT

Form

4

Source Type

fda

Accession

0001193125-26-354313

Alert Tier

6